PURPOSE To provide evidence-based recommendations to practicing clinicians on
management of patients with stage III non–small-cell lung cancer (NSCLC). METHODS An …

Objectives Stage III non-small cell lung cancer (NSCLC) describes a heterogeneous
population with disease presentation ranging from apparently resectable tumors with occult …

Lung cancer is the leading cause of cancer death worldwide. Majority of newly diagnosed
lung cancers are non-small cell lung cancer (NSCLC), of which up to half are considered …

Objective To develop evidence-based guidelines on best available treatment options for
patients with stage IIIB non-small cell lung cancer (NSCLC). Methods A review was …

Background The surgical treatment of stage I and II non-small cell lung cancer (NSCLC)
continues to evolve in the areas of intraoperative lymph node staging (specifically the issue …

Study objectives Stage IIIA non-small cell lung cancer represents a relatively heterogeneous
group of patients with metastatic disease to the ipsilateral mediastinal (N2) lymph nodes and …

Background The treatment of stage I and II non-small cell lung cancer (NSCLC) in patients
with good or low surgical risk is primarily surgical resection. However, this area is …

Purpose The panel updated the American Society of Clinical Oncology (ASCO) adjuvant
therapy guideline for resected non–small-cell lung cancers. Methods ASCO convened an …

Background Stage IV non-small cell lung cancer (NSCLC) is a treatable, but not curable,
clinical entity in patients given the diagnosis at a time when their performance status (PS) …

ASCO Rapid Recommendations Updates highlight revisions to select ASCO guideline
recommendations as a response to the emergence of new and practice-changing data. The …